Market News & Trends
Atlas Nanotech Targets the World’s Largest Consumer Health Products Companies
Costas, Inc. DBA/Atlas Nanotech, (the Company) is currently in discussions to license their proprietary nanotechnology vitamin a (retinol) based crystalline eye drops known under the…
CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals
CURE Pharmaceutical recently announced it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and…
PromoCell Now Offers In Vitro Disease Models That Could Lead to New Therapies
PromoCell now offers cell disease models covering a wide range of diseases, including diabetes type 1 and 2, respiratory diseases, such as COPD and asthma,…
New Study From Tufts Center for the Study of Drug Development Establishes Benchmarks
While more than 90% of all contract vendor assessments conducted by drug sponsors ultimately lead to vendors being qualified to provide services, large sponsors have…
Centogene Signs Collaboration Agreement With Pfizer
CENTOGENE recently announced a new data access and collaboration agreement with Pfizer Inc. The agreement grants Pfizer access to CENTOGENE’s data repository, which may be…
Aravive & AstraZeneca Announce Initiation of Randomized Phase 1/2 Study
Aravive, Inc. and AstraZeneca recently announced that an investigator-sponsored Phase 1/2 clinical trial of AVB-500, a GAS6/AXL inhibitor, in combination with durvalumab, a PD-L1 inhibitor,…
NervGen Pharma Expands Platform Into Alzheimer’s Disease
NervGen Pharma Corp. recently announced a research initiative to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis,…
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials
Menlo Therapeutics Inc. recently announced it has completed enrollment of patients in its two Phase 3 clinical trials evaluating the safety and efficacy of once-daily…
Artelo Biosciences Announces Selection of Clinical Research Organization
Artelo Biosciences, Inc. recently announced it has selected Aptus Clinical Ltd. (Aptus) as its contract research organization (CRO) for the company’s planned Phase 1b/2a randomized,…
Disc Medicine Completes $50-Million Series A Financing, Enters Exclusive License Agreement With AbbVie
Disc Medicine recently announced the completion of a $50-million Series A financing. The company’s novel approach focuses on targeting hepcidin, a key regulator of iron…